MAPT and supranuclear palsy, progressive, 1: Unlike the epitopes above, pTau epitopes phosphorylated at pSer396 or pSer396/pSer404 (PHF1) were not significantly different between FTLD-MAPT and controls (Fig. 2F and G), while PiD and PSP cases were found to be significantly increased versus controls, (PiD: pSer396 P < 0.0001; PHF1 P < 0.0001; PSP: pSer396 P < 0.0001; PHF1 P < 0.0001).